Royce & Associates LP Increases Stake in Catalyst Pharmaceuticals, Inc. $CPRX

Royce & Associates LP grew its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 28.6% during the 3rd quarter, HoldingsChannel reports. The firm owned 2,034,965 shares of the biopharmaceutical company’s stock after buying an additional 452,103 shares during the period. Royce & Associates LP’s holdings in Catalyst Pharmaceuticals were worth $40,089,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Rafferty Asset Management LLC boosted its position in Catalyst Pharmaceuticals by 64.1% during the third quarter. Rafferty Asset Management LLC now owns 157,044 shares of the biopharmaceutical company’s stock worth $3,094,000 after acquiring an additional 61,328 shares during the last quarter. American Century Companies Inc. boosted its holdings in shares of Catalyst Pharmaceuticals by 43.8% during the 3rd quarter. American Century Companies Inc. now owns 2,528,186 shares of the biopharmaceutical company’s stock worth $49,805,000 after purchasing an additional 770,198 shares during the last quarter. Hohimer Wealth Management LLC grew its position in shares of Catalyst Pharmaceuticals by 37.1% in the third quarter. Hohimer Wealth Management LLC now owns 16,413 shares of the biopharmaceutical company’s stock valued at $323,000 after purchasing an additional 4,439 shares in the last quarter. Choreo LLC acquired a new stake in shares of Catalyst Pharmaceuticals in the third quarter valued at approximately $412,000. Finally, Fox Run Management L.L.C. purchased a new position in Catalyst Pharmaceuticals during the third quarter worth approximately $258,000. 79.22% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Catalyst Pharmaceuticals news, Director Molly Harper sold 26,746 shares of Catalyst Pharmaceuticals stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $23.25, for a total value of $621,844.50. Following the completion of the transaction, the director directly owned 2,360 shares of the company’s stock, valued at $54,870. The trade was a 91.89% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 10.40% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on CPRX shares. Citigroup upped their target price on Catalyst Pharmaceuticals from $31.00 to $33.00 and gave the company a “buy” rating in a report on Friday, November 7th. Oppenheimer reissued an “outperform” rating and issued a $33.00 price target on shares of Catalyst Pharmaceuticals in a research note on Friday, November 7th. Weiss Ratings reissued a “buy (b-)” rating on shares of Catalyst Pharmaceuticals in a research note on Monday, December 29th. Finally, Wall Street Zen raised Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Sunday, November 16th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $32.67.

Catalyst Pharmaceuticals Stock Down 7.2%

Shares of NASDAQ CPRX opened at $23.08 on Friday. The business’s 50 day moving average is $23.86 and its two-hundred day moving average is $22.22. Catalyst Pharmaceuticals, Inc. has a 52-week low of $19.05 and a 52-week high of $26.58. The firm has a market cap of $2.82 billion, a price-to-earnings ratio of 13.66, a PEG ratio of 0.77 and a beta of 0.74.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).